ABBV vs ISRG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intuitive Surgical, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Intuitive Surgical, Inc. · Healthcare
$399.52
+22.4% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
ISRG has more upside to fair value
(+22.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ISRG |
| Current Price |
$261.70 |
$399.52 |
| Fair Value Estimate |
$259.04 |
$488.97 |
| Upside to Fair Value |
-1.0%
|
+22.4%
|
| Market Cap |
$462.4B |
$141.1B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
30.7x
|
| Price / Sales |
7.2x
|
12.8x
|
| Price / FCF |
23.6x
|
44.0x
|
| Revenue Growth YoY |
+10.2%
|
+18.5%
|
| Gross Margin |
71.5%
|
66.7%
|
| Operating Margin |
29.3%
|
31.3%
|
| Return on Equity |
-136.5%
|
17.8%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
2.28%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Intuitive Surgical develops, produces, and commercializes the da Vinci surgical system and the Ion endoluminal system, along with instruments, accessories, training, and digital solutions that drive a large installed-base and recurring-revenue model. Business quality is high: TTM gross margin of 66.7%, operating margin of 31.3%, net margin of 28.4%, ROE of 17.8%, and revenue growth of 18.5% with …
Accumulation Zones
| Metric |
ABBV |
ISRG |
| Zone Low |
$194.28 |
$366.73 |
| Zone High |
$220.18 |
$415.62 |
| In Buy Zone? |
No
|
Yes
|